You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
THINPREP PAP |
||
Geisinger Epic Procedure Code: Screen: LAB4102. Diagnostic: LAB4103
Geisinger Epic ID: Screen 19360. Diagnostic 19376
|
||
SPECIMEN COLLECTION |
||
Specimen type: |
Gynecologic specimens (cervical screening) | |
Preferred collection container: |
||
Specimen required: |
ThinPrep vial with rinsed spatula, brush or broom. | |
Special notes: |
The collection device is rinsed in the PreservCyt but not submitted in the vial. | |
Patient preparation: |
No vaginal lubricants to be used prior to collection of thin-prep specimen. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
The ThinPrep vial is labeled with two identifiers (patient name and medical record number). After sampling, the spatula, brush or broom is swished and swirled in the PreservCyt solution. The vial with cellular suspension is submitted to the laboratory. The collection device is not submitted in the vial. | |
Transport temperature: |
Room temperature. | |
Rejection criteria: |
Inadequate patient identifiers on specimen, unlabeled specimen, discrepancy between patient specimen and requisition information, improper collection. | |
TEST DETAILS |
||
Interpretation guide: |
Updated Consensus Guidelines for managing abnormal cervical cancer screening tests and cancer Precursors algorithms. | |
CPT code(s): |
88142 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Cytologic evaluation. | |
Methodology: |
Microscopic Examination |
|
Synonyms: |
Pap with or without HPV, Pap, Pap screen, Pap diagnostic Liquid-based Pap ThinPrep, Thinlayer Pap Cytology, Cervical screening, Vaginal screening PreservCyt solution
|
|
Clinical significance: |
Cervical screening for the detection of premalignant lesions of the cervix which can be eradicated, thus reducing the occurrence of carcinoma of the cervix. | |
Doctoral Director(s:) |
Sara Monaco MD | |
| Review Date: | 12/23/2022 | |